Advertisment

Biological E's Covid vaccine Corbevax gets emergency use nod for 12-18 age group

author-image
Jasleen Kaur
New Update
Biological E's Covid vaccine Corbevax gets emergency use nod for 12-18 age group
Advertisment
New Delhi, February 21: The Drugs Controller General of India (DCGI) on Monday gave an emergency use nod to Hyderabad-based pharmaceutical company Biological E's Covid-19 vaccine Corbevax for children aged 12-18 years. It is India's third homegrown Covid-19 vaccine.
Advertisment
In a statement, Biological E Limited said, "India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19, has received emergency use authorisation (EUA) from India's drug regulator for 12-18 age group." publive-imageEarlier, Dr NK Arora, chairman, India's Covid-19 working group of the National Technical Advisory Group on Immunisation (NTAGI),had stated that India's third homegrown Covid-19 vaccine Corbevax is safe and offers good immunogenicity and higher antibody levels than some other vector Covid-19 vaccines. Corbevax  is a two-dose vaccine. India's third homegrown Covid-19 vaccine Corbevax will be administered in two doses, according to reports. This is the third vaccine approved for use in children aged 12 and above in India, joining Zydus Cadila's DNA shot ZyCoV-D and Bharat Biotech's Covaxin.
Advertisment
Also read | Omicron BA.2 unlikely to cause another Covid-19 surge Dr NK Arora said, "Protein subunit vaccines are safe vaccines, the immunogenicity is very good and local reactions are also less as compared to some of the other vaccines like vector vaccine or mRNA vaccine. Another very important dimension about this Covid-19 vaccine is that compared to some of the vector vaccines, the antibody levels are much higher." "Corbevax is called a protein subunit and currently we have an example of hepatitis B vaccine, which is also similarly a protein subunit vaccine. Corbevax and the other vaccine in India, we have Covovax from Serum Institute. So, we have now these two vaccines and Corbevax as we know that it has been approved for children in the 12-18 age group," he said. publive-imageThe NTAGI chief said the vaccine had shown "more activity" against Delta in comparison to Omicron. The Government of India had placed an order with Hyderabad-based Pharmaceutical company Biological E for five crore doses of 'Corbevax' Covid-19 vaccine with each dose costing Rs 145.
Advertisment
Also read | Covid-19: Classes 5, 8 board exams cancelled in Haryana for one year The Centre had earlier placed an order for 30 crore Corbevax doses on August 21 last year, they added. publive-image-PTC News-
covid-19 covid-vaccine dcgi covid-19-vaccine corbevax corbevax-children biological-e-limited
Advertisment

Stay updated with the latest news headlines.

Follow us:
Advertisment